In the early days of the COVID-19 pandemic, researchers struggled to grasp the rate of the virus's spread and the number of ...

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

Robert Snyder’s new book draws upon the stories of 45 New Yorkers representing a wide spectrum of professions.

“The latest COVID-19 booster available in New Zealand is the Pfizer-BioNTech’s Comirnaty mRNA vaccine. This targets the Omicron JN.1 variant which is the most common strain currently circulating. This ...

The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

Our immune system does not recognize it and there is no or very little antigen antibody response or, just as problematic ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...

Long COVID symptoms persisted for up to two years in more than half of the individuals who experienced the condition, according to new research published in BMC Medicine.

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. “It still feels kind of incomplete,” said ...